Association of hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism with renal cell carcinoma and prostate cancer susceptibility: a meta-analysis

Hong-Yan Li†, Tianbiao Zhou‡*, Wenshan Lin‡†, Shujun Lin‡† and Hongzhen Zhong‡

Abstract
Background: This meta-analysis was performed to evaluate the relationship between hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism and the susceptibility to renal cell carcinoma (RCC) and prostate cancer (PCa).

Methods: Association investigations were identified and included from the Embase, Cochrane Library and PubMed databases on March 1, 2018, and eligible investigations were analyzed by meta-analysis. Odds ratios (OR) were used to express the dichotomous data, and the 95% confidence intervals (CI) were also calculated.

Results: In this meta-analysis, we found that the AA genotype of HIF1α 1790G/A was positively associated with the risk of RCC in overall populations, Caucasians, but not for Asians. G allele and GG genotype were not associated with the susceptibility of RCC in overall populations, Caucasians, and Asians. The G allele was negatively associated with PCa susceptibility in overall populations, Asians, but not for Caucasians. GG genotype was negatively associated with PCa susceptibility in Asians, but not for overall populations and Caucasians. HIF1α 1790G/A AA genotype was not associated with PCa susceptibility in overall populations of Caucasians or Asians.

Conclusion: AA genotype of HIF1α 1790G/A was positively associated with RCC risk in overall populations and Caucasians. Furthermore, the G allele was negatively associated with prostate cancer susceptibility in overall populations, Asians, and GG genotype was negatively associated with PCa susceptibility in Asians.

Keywords: Renal cell carcinoma, Prostate cancer, Hypoxia-inducible factor-1α (HIF1α), 1790G/A gene polymorphism, Meta-analysis

Background
Renal cell carcinoma (RCC) is one of the most commonly occurring types of tumors in the urogenital system and accounts for ~ 85% of all kidney tumors [1–4]. RCC is not sensitive to conventional chemotherapy and radiotherapy, and its prognosis remains poor [1]. Prostate cancer (PCa) is a complex disease, and is the fifth leading cause of cancer death in men worldwide [5]. The screening projection for PCa is still unclear and recent large clinical trials have failed to exert notable reduction in the prostate-specific mortality and the all-cause mortality [6]. The current evidence shows that RCC and PCa are Von Hippel-Lindau tumor suppressor (VHL)-related cancers [7–10]. VHL protein is an E3 ubiquitin ligase that targets hypoxia inducible factor 1α (HIF1α) to the proteasome for degradation [11]. The current literature indicates that genetic factors are significant contributors to cancers risk [12–15].

Hypoxia inducible factor 1α (HIF1α) is the central regulator of the cellular response to low oxygen, and the activity of HIF1α is down-regulated in various human pathologies [16, 17]. During hypoxia, reduced oxygen availability can inhibit these HIF hydroxylase enzymes, and lead to HIF1α protein accumulation, which may translocate to the cell nucleus, bind to the HIF1β, and
induce the transcription of some HIF target genes [18]. HIF1α regulates tumor cell proliferation, invasion, migration, and resistance to radiotherapy [16, 19]. Consequently, given the importance of HIF signaling in disease, there is considerable interest in developing strategies to modulate HIF1α activity and to induce downstream signaling events. HIF1α 1790G/A (rs11549467) gene polymorphism is one of the most important gene polymorphism for certain cancers, such as PCa, and RCC. However, the available evidence is inadequate due to inconsistencies between studies and an overall lack of data. This meta-analysis was performed to investigate whether the HIF1α 1790G/A (rs11549467) gene polymorphism is associated with RCC, PCa susceptibility.

Methods

Search strategy

Retrieval of the relevant published reports were conducted in the electronic databases of Embase, Cochrane Library and PubMed on March 1, 2018, and eligible original articles were recruited into this meta-analysis. The key phrases for retrieval consisted of (“hypoxia-inducible factor OR hypoxia-inducible factor-1α” OR “HIF1α”) and (“renal cell carcinoma” OR “renal carcinoma” OR “renal cancer” OR “RCC” OR “prostatic carcinoma” OR “prostatic cancer” OR “prostate cancer” OR “prostate carcinoma”).

Inclusion and exclusion criteria

Inclusion criteria: (1) an endpoint of RCC, PCa; (2) two comparison groups (case vs. control); (3) the presence of detailed data for the genotype distribution.

Exclusion criteria: (1) case reports, review articles and editorials; (2) preliminary results not on HIF1α 1790G/A gene polymorphism or RCC, PCa susceptibility; (3) investigations of the role HIF1α gene expression in disease.

Data extraction and synthesis

The following information from each eligible study was independently extracted by two investigators: first author’s surname, year of publication and the number of cases and controls for HIF1α 1790G/A genotypes. Frequencies of genotypes for HIF1α 1790G/A were calculated for each case group and control group, from the corresponding genotype distributions. The results were compared, and disagreement was resolved by discussion. Consistency of data extracted by the 2 researchers was evaluated and disagreements were resolved by discussion.

Statistical analysis

All statistical analyses were performed using Cochrane Review Manager Version 5 (Cochrane Library, UK). The pooled statistic was determined using the fixed effects model (Mantel-Haenszel method), and a random effects model (DerSimonian-Laird method) was conducted when the P-value from the heterogeneity test was less than 0.1. Odds ratios (OR) were used to express the dichotomous data, and 95% confidence intervals (CI) were also calculated. A P < 0.05 was required for the pooled OR to be statistically significant. I² was used to assess the heterogeneity among the included studies.

Results

Study characteristics for association of the HIF1α 1790G/A gene polymorphism with RCC susceptibility

Four studies [20–23] were recruited into our investigation of the relationship between the HIF1α 1790G/A gene polymorphism and RCC susceptibility (Table 1). Data of interest was extracted by the first author’s surname, year of publication and the number of cases and controls for the HIF1α 1790G/A genotype (Table 1). The 4 included investigations contained 1139 case series and 1364 controls.

Study characteristics for association of the HIF1α 1790G/A gene polymorphism with PCa susceptibility

Four studies [24–27] were recruited into our meta-analysis to explore the relationship between the HIF1α 1790G/A gene polymorphism and PCa risk (Table 1). Those four investigations contained 2124 case series and 2476 controls.

Association of the HIF1α 1790G/A gene polymorphism with RCC susceptibility

In this meta-analysis, we found that the AA genotype of HIF1α 1790G/A was positively associated with RCC risk in overall populations (OR = 3.09, 95% CI: 1.38–6.92, P = 0.006; Fig. 1 and Table 2) and Caucasians, but not for Asians. G allele and GG genotype were not associated with RCC risk in overall populations (G: OR = 0.68, 95% CI: 0.47–0.99, P = 0.44; Fig. 1 and Table 2), Caucasians, or Asians.

Association of the HIF1α 1790G/A gene polymorphism with PCa susceptibility

The G allele was negatively associated with PCa susceptibility in overall populations and Asians, but not for Caucasians (Overall populations: G: OR = 0.68, 95% CI: 0.47–0.99, P = 0.04; Fig. 2 and Table 2). GG genotype was negatively associated with PCa susceptibility in Asians, but not for overall populations or Caucasians (Overall populations: G: OR = 0.69, 95% CI: 0.47–1.00, P = 0.05; Fig. 2 and Table 2). However, HIF1α 1790G/A AA genotype was not associated with PCa susceptibility in overall populations of Caucasians or Asians (Overall populations: OR = 3.25, 95% CI: 0.13–79.90, P = 0.47; Fig. 2 and Table 2).
Table 1 Characteristics of studies evaluating the effects of hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism on renal cancer and prostate cancer risk

| Cancer Types | Author, Year | Country | Ethnicity | Case   | Control | Odds Ratio | Odds Ratio |
|--------------|--------------|---------|-----------|--------|---------|------------|------------|
|              |              |         |           | −      | +       | Total      | −          |
| Renal cancer | Clifford 2001 | UK      | Caucasian | 18     | 27      | 45         | 31         |
|              | Ollerenshaw 2004 | UK     | Caucasian | 89     | 84      | 173        | 117        |
|              | Morris 2009  | Poland  | Caucasian | 63     | 63      | 126        | 255        |
|              | Qin 2012     | China   | Asian     | 50     | 50      | 100        | 108        |
| Prostate cancer | Chau 2005 | USA    | Mix       | 424    | 487     | 911        | 555        |
|              | Orr-Urtreger 2007 | Israel | Caucasian | 51     | 47      | 98         | 167        |
|              | Li 2007      | USA     | Mix       | 303    | 321     | 624        | 433        |
|              | Li 2012      | China   | Asian     | 46     | 30      | 76         | 86         |

Fig. 1 Association between hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism and renal cancer susceptibility in overall populations
In this in-depth meta-analysis, the results indicate that the AA genotype of HIF1α 1790G/A is positively associated with the risk of RCC in overall populations and Caucasians, but not for Asians. The G allele and GG genotype are not associated with the susceptibility of RCC in overall populations, Caucasians, and Asians. The G allele is negatively associated with PCa susceptibility in overall populations and Asians, but not for Caucasians. The GG genotype is negatively associated with PCa susceptibility in Asians, but not for overall populations or Caucasians. However, the HIF1α 1790G/A AA genotype is not associated with PCa susceptibility in overall populations, Caucasians or Asians.

Previous, related meta-analyses have been conducted. Li et al. [28] reported that for the 1790G/A polymorphism, the G allele was significantly associated with a higher risk of urinary cancers in Asians. Anam et al. [29] conducted a meta-analysis using the genome wide association method including 19 case-control studies with a total sample size 10,654, and reported that the HIF1α 1790 G/A gene polymorphism significantly increased the risk of cancer in both Asian and Caucasian populations. Zhou et al. [30] performed a meta-analysis of 28 case-control studies of the relationship between the HIF1α G1790A gene polymorphism and the risk of cancer, and reported that the G with A of HIF-1α G1790A gene polymorphism is a notable risk factor of cancer, especially for RCC, lung cancer, pancreatic cancer, and head and neck cancer. These meta-analyses did not assess the relationship between the HIF1α 1790G/A gene polymorphism and RCC and PCa susceptibility by races. Our results indicate that AA genotype of HIF1α 1790G/A was positively associated with RCC risk in overall populations and Caucasians. Furthermore, the G allele was negatively associated with PCa susceptibility in overall populations and Asians, and the GG genotype was negatively associated with PCa susceptibility in Asians. However, the sample sizes were small and these results need to be treated with caution.

Considering our results and the available literature, we suspected that the G allele and GG genotype were negatively associated with PCa susceptibility, and that the AA genotype was a risk factor to induce the onset of RCC. The hypothesis was as follows: Under both normoxic conditions and hypoxia, the HIF-1α G1790A gene polymorphism would be associated with increased transcription activities and enhanced angiogenesis compared to the wild type [31, 32]. The cause of the enhance transactivation capacity could be the alteration of stability of variant proteins or the enhanced recruitment of transcriptional co-factors such as SRC-1 and CBP/p300 that

| Cancer Type | Group and subgroups | Studies Number | Q test P-value | Model selected | OR (95%CI) | P  |
|-------------|---------------------|---------------|---------------|---------------|------------|----|
| Renal cancer | G vs A              | Overall       | <0.00001      | Random        | 0.65 (0.26,1.67) | 0.38 |
|             |                     | Caucasian     | 0.0004        | Random        | 0.61 (0.16,2.30) | 0.46 |
|             |                     | Asian         | -             | Fixed         | 0.86 (0.55,1.33) | 0.49 |
|             | AA vs AG + GG       | Overall       | 0.76          | Fixed         | 3.09 (1.38,6.92) | 0.006|
|             |                     | Caucasian     | 0.76          | Fixed         | 3.09 (1.38,6.92) | 0.006|
|             |                     | Asian         | -             | Fixed         | -            | -   |
|             | GG vs AG + AA       | Overall       | <0.00001      | Random        | 0.63 (0.20,2.03) | 0.44|
|             |                     | Caucasian     | <0.00001      | Random        | 0.59 (0.11,3.31) | 0.55|
|             |                     | Asian         | -             | Fixed         | 0.85 (0.55,1.33) | 0.48|
| Prostate cancer | G vs A             | Overall       | 0.49          | Fixed         | 0.68 (0.47,0.99) | 0.04|
|             |                     | Caucasian     | -             | Fixed         | 0.67 (0.09,4.74) | 0.68|
|             |                     | Asian         | -             | Fixed         | 0.58 (0.36,0.91) | 0.02|
|             | AA vs AG + GG       | Overall       | -             | Fixed         | 3.25 (0.13,79.90) | 0.47|
|             |                     | Caucasian     | -             | Fixed         | 3.25 (0.13,79.90) | 0.47|
|             |                     | Asian         | -             | Fixed         | -            | -   |
|             | GG vs AG + AA       | Overall       | 0.50          | Fixed         | 0.69 (0.47,1.00) | 0.05|
|             |                     | Caucasian     | -             | Fixed         | 0.66 (0.09,4.76) | 0.68|
|             |                     | Asian         | -             | Fixed         | 0.58 (0.36,0.92) | 0.02|
interact with HIF-1α [33]. HIF-1α G1790A gene polymorphism has been detected within the oxygen-dependent degradation/pVHL binding domain in exon 12 of the HIF-1α gene, which induces increased transcription activity compared to wild type [31]. In addition, regulatory region mutations may interfere with different post-translational modifications of HIF-1α and result in enhanced protein stability [34, 35]. HIF-1α G1790A has been associated with enhanced tumor-produced HIF-1α and cancer progression [36]. BHLHE41 is a specific transcriptional target of HIF-1α, and the HIF-1α G1790A polymorphism creates a HIF-binding site to mediate the upregulation of BHLHE41 [37]. However, there was rare study to detect the functional roles of the G, GG, and AA genotypes in the transcription and other related activities of HIF-1α. In this study, we found that the negative association of G allele with susceptibility of prostate cancer in Asians. We suspected that G allele of HIF-1α G1790A might be associated with low levels of HIF-1α and might be negative association of G allele with prostate cancer risk. However, more studies should be performed to confirm it.

There were some limitations in our meta-analysis, as the study sample sizes were low, and we did not explore sources of variability between studies such as adjusting variables, age distribution, and sources of controls. These results should be treated with caution.

**Conclusion**

The present results support the hypothesis that the AA genotype of HIF1α 1790G/A is positively associated with RCC risk in overall populations and Caucasians. Furthermore, the G allele is negatively associated with PCa susceptibility in overall populations and Asians, and the GG...
genotype is negatively associated with PCa susceptibility in Asians. However, additional investigations are required to confirm these relationships.

Abbreviations
CI: confidence intervals; HIF1α: hypoxia-inducible factor-1α; OR: Odds ratios; PCa: prostate cancer; RCC: renal cell carcinoma

Acknowledgments
Not applicable.

Authors’ contributions
TBZ was in charge of conceiving and designing the study. TBZ and HYL were responsible for the collection of data and performing the statistical analysis and manuscript preparation. WSL, SJL and HZZ were responsible for checking the data. All authors were responsible for drafting the manuscript, reading it, and approving the final version.

Funding
This study was supported by Guangzhou Medical Key Discipline Construction Project (2017-2019).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, Guangzhou 510800, China. 2Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, 515041, No 69 Donggao Road, Shantou, China.

Received: 9 April 2019 Accepted: 8 August 2019

References
1. Zhang XL, Xu G, Zhou Y, Yan J. MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3. Oncol Lett. 2018;15(4):6003–8.
2. Ying G, Wu R, Xia M, Fei X, He QE, Zha C, Wu F. Identification of eight key miRNAs associated with renal cell carcinoma: a meta-analysis. Oncol Lett. 2018;16(5):5847–55.
3. Li X, Qin Z, Xue J, Zhang J, Zheng Y, Xu W, Xu T, Zhou Q. Genetic variants in macrophage colony-stimulating factor are associated with risk of renal cell carcinoma in a Chinese population. Int J Biol Markers. 2018;33(3):321–8.
4. Zhong Z, Li H, Zhong H, Zhou T, Xie W, Lin Z. A systematic review and meta-analysis of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility. BMC medical genetics. 2018;19(1):128.
5. Zhong Z, Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1α gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate. 2007;67(12):1354–61.
6. Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju YB, Yin JL. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian J Androl. 2012;14(6):864–9.
7. Chetram M, Bethea D, Odero-Marah V, Don-Salu-Hewage A, Jones K, Hinton C. ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem. 2013;376(1–2):63–71.
8. Filibos and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors. Am J Pathol. 2015;185(1):3900–101.
9. Anwar SL, Haryono SJ, Anyandono T, Datasean IG. Screening of BRCA1/2 mutations using direct sequencing in Indonesian familial breast Cancer cases. Asian Pac J Cancer Prev. 2016;17(4):1987–91.
10. Anwar SL, Wulaningsih W, Watkins J. Profile of the breast cancer susceptibility marker rs4242979 identifies a role for miRNAs. Cancer Biol Med. 2017;14(4):387–95.
11. Ouyang Y, Li H, Bu J, Li X, Chen Z, Xiao T. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients’ survival: a meta-analysis. Int J Mol Markers. 2016;31(3):229–34.
12. Dodd MS, Sousa Falho MLD, Montes Aparicio ON, Kerr M, Timm KN, Griffin JL, Glazt JFC, Tyler DJ, Heather LC. Fatty acids prevent hypoxia-inducible factor-1α signaling through decreased succinate in diabetes. JACC Basic Transl Sci. 2018;3(4):485–98.
13. Xie W, Liu L, He H, Yang K. Prognostic value of hypoxia-inducible factor-1 alpha in nasopharyngeal carcinoma: a meta-analysis. Int J Mol Markers. 2018;14(2):1–9.
14. Anticancer Res. 2019;29(11):4337–43.
15. Qin C, Cao Q, Ju X, Wang M, Meng X, Zhu J, Yan F, Li P, Ding Q, Chen J, et al. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol. 2012;23(4):981–9.
16. Zhang ZW, Newcomb P, Hollowood A, Feakins R, Mooghen M, Storey A, Farthing MJ, Alderson D, Holly J. Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res. 2003(9):2511–6.
17. Blows MW, Woo TK, Lee K, Gao Y, Zhang Z, Hebert SC, et al. CRISPR/Cas9 genome engineering of human pluripotent stem cells. Nat Biotechnol. 2015;33(10):992–7.
18. Li H, Shukla A, Patel AK, Price JS, Fontanesi JA, et al. Identification of an HIF-1α variant associated with a reduced risk of prostate cancer in African Americans. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1836–41.
19. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate. 2007;67(11):1354–61.
28. Li D, Liu J, Zhang W, Ren J, Yan L, Liu H, Xu Z. Association between HIF1A P582S and A588T polymorphisms and the risk of urinary cancers: a meta-analysis. PLoS One. 2013;8(5):e63445.
29. Anam MT, Ishika A, Hossain MB. Jesmin: a meta-analysis of hypoxia inducible factor-1-alpha (HIF1A) gene polymorphisms association with cancers. Biomarker Res. 2015;3:29.
30. Zhou Y, Lin L, Wang Y, Jin X, Zhao X, Liu D, Hu T, Jiang L, Dan H, Zeng X, et al. The association between hypoxia-inducible factor-1 alpha gene G1790A polymorphism and cancer risk: a meta-analysis of 28 case-control studies. Cancer Cell Int. 2014;14:37.
31. Tanimoto K, Yoshiga H, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24(11):1779–83.
32. Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol. 2009;27(3):238–45.
33. Carrero P, Okamoto K, Courmaileau P, O’Brien S, Tanaka H, Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol. 2000;20(1):402–15.
34. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther. 2005;4(11):1222–5.
35. Sharma S, Kapahi R, Sambyal V, Guleria K, Manjari M, Sudan M, Uppal MS, Singh NR. No association of hypoxia inducible factor-1alpha gene polymorphisms with breast cancer in north-west Indians. Asian Pac J Cancer Prev. 2014;15(22):9973–8.
36. Wang X, Liu Y, Ren H, Yuan Z, Li S, Sheng J, Zhao T, Chen Y, Liu F, Wang F, et al. Polymorphisms in the hypoxia-inducible factor-1alpha gene confer susceptibility to pancreatic cancer. Cancer Biol Ther. 2011;12(5):383–7.
37. Grampp S, Schmid V, Salama R, Lauer V, Kranz F, Platt JL, Smythies J, Choudhry H, Goppelt-Stuebe M, Ratcliffe PJ, et al. Multiple renal cancer susceptibility polymorphisms modulate the HIF pathway. PLoS Genet. 2017; 13(7):e1006872.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.